

Supplementary Table 4. Baseline characteristics of the patients treated with systemic therapy, external beam radiation therapy, best supportive care, and miscellaneous therapies (n=1,684)

Variable	Systemic therapy (n=224, 3.7%)	External beam radiation therapy (n=61, 1.1%)	Best supportive care (n=1,295, 21.7%)	Miscellaneous therapies* (n=104, 1.7%)
Demographic variable				
Age (years)	54.0 (47.5-64.0)	55.0 (47.0-64.0)	61.5 (52.5-71.0)	53.2 (48.0-57.0)
Sex (male)	189 (84.4)	48 (78.7)	1,030 (79.5)	89 (85.6)
Diabetes	35 (15.6)	8 (13.1)	302 (23.3)	11 (10.6)
Hypertension	44 (19.8)	10 (17.2)	366 (29.9)	23 (22.1)
Body mass index (kg/m ²)	23.1 (21.3-24.9)	22.9 (20.9-25.4)	23.6 (21.5-26.1)	23.3 (21.2-25.0)
Smoking	111 (50.2)	29 (48.3)	535 (43.7)	57 (54.8)
Etiology	n=205	n=55	n=1,037	n=99
HBV [†]	158 (77.1)	47 (85.5)	694 (66.9)	84 (84.8)
HCV	15 (7.3)	3 (5.5)	132 (12.7)	9 (9.1)
Alcohol	22 (10.7)	5 (9.1)	192 (18.5)	4 (4.0)
Others	10 (4.9)	0	19 (1.8)	2 (2.0)
Performance status [‡]	n=164	n=38	n=772	n=80
0	98 (59.8)	23 (60.5)	403 (52.2)	51 (63.8)
1	53 (32.3)	10 (26.3)	187 (24.2)	25 (31.2)
2	6 (3.7)	2 (5.3)	89 (11.5)	4 (5.0)
3	2 (1.2)	2 (5.3)	53 (6.9)	0
4	5 (3.0)	1 (2.6)	40 (5.2)	0
Ascites	n=224	n=61	n=1,295	n=104
None	129 (57.6)	35 (57.4)	666 (51.4)	76 (73.1)
Mild	63 (28.1)	20 (32.8)	357 (27.6)	25 (24.0)
Moderate to severe	32 (14.3)	6 (9.8)	272 (21.0)	3 (2.9)
Encephalopathy	n=221	n=61	n=1,286	n=103
None	213 (96.4)	57 (93.4)	1,218 (94.7)	102 (99.0)
Mild to moderate (grade 1 or 2)	8 (3.6)	4 (6.6)	52 (4.0)	1 (1.0)
Severe (grade 3 or 4)	0	0	16 (1.2)	0
Laboratory variable				
Total bilirubin (mg/dL)	1.1 (0.8-1.7)	1.2 (0.8-1.9)	3.4 (0.8-3.3)	1.3 (0.6-1.2)
Serum albumin (g/dL)	3.6 (3.2-4.0)	3.6 (3.0-3.9)	3.3 (2.8-3.7)	3.8 (3.4-4.2)
Alanine aminotransferase (IU/L)	46.0 (30.0-75.0)	49.0 (34.0-83.0)	67.0 (24.5-85.0)	80.4 (22.0-78.6)
Platelet count (10 ⁹ /L)	171.0 (123.0-244.0)	142.5 (112.0-204.0)	165.8 (86.5-218.0)	174.4 (104.0-221.0)
Prothrombin time (INR)	1.12 (1.03-1.19)	1.15 (1.07-1.29)	1.23 (1.06-1.33)	1.10 (1.02-1.16)
Creatinine (mg/dL)	0.90 (0.71-1.00)	0.80 (0.70-0.94)	0.97 (0.70-1.10)	0.80 (0.69-0.94)
Sodium (mmol/L)	138.0 (135.0-140.0)	138.0 (134.0-140.0)	136.0 (134.0-140.0)	138.6 (137.0-140.0)
Glucose (mg/dL)	106.5 (93.0-134.0)	116.0 (95.0-129.5)	143.3 (95.5-161.0)	114.4 (90.0-123.0)
Total cholesterol (mg/dL)	164.5 (136.0-196.0)	165.0 (122.0-200.0)	156.1 (118.5-185.5)	163.4 (136.0-187.0)
Alpha-fetoprotein (ng/mL)	1,750.0 (84.3-19,982.2)	726.0 (33.1-8,592.2)	11,658.3 (8.2-3,482.2)	12,250.7 (21.3-24,235.3)
PIVKA-II (mAU/mL)	2,000.0 (818.0-2,000.0)	685.0 (88.5-2,000.0)	1,814.0 (83.5-2,000.0)	2,730.0 (292.0-2,000.0)

Supplementary Table 4. Continued

Variable	Systemic therapy (n=224, 3.7%)	External beam radiation therapy (n=61, 1.1%)	Best supportive care (n=1,295, 21.7%)	Miscellaneous therapies* (n=104, 1.7%)
Child-Turcotte-Pugh class	n=212	n=58	n=1,169	n=98
A	129 (60.8)	27 (46.6)	491 (37.9)	78 (79.6)
B	75 (35.4)	30 (51.7)	485 (37.5)	19 (19.4)
C	8 (3.8)	1 (1.7)	193 (14.9)	1 (1.0)
MELD score	8.9 (7.5-10.9)	9.7 (7.8-11.3)	12.0 (8.2-14.5)	8.5 (7.0-9.8)
MELD-Na score	11.3 (8.9-14.1)	12.4 (9.4-15.1)	14.4 (9.6-18.4)	9.8 (7.5-11.4)
Tumor variable				
Tumor number	n=224	n=61	n=1,289	n=104
1	74 (33.0)	32 (52.5)	598 (46.4)	50 (48.1)
2	17 (7.6)	8 (13.1)	138 (10.7)	14 (13.5)
3	8 (3.6)	0	30 (2.3)	7 (6.7)
4	3 (1.3)	0	23 (1.8)	1 (1.0)
≥5	122 (54.5)	21 (34.4)	500 (38.8)	32 (30.8)
Maximal tumor diameter (cm)	7.0 (4.8-10.0)	4.2 (2.5-8.0)	6.0 (2.9-9.0)	7.1 (4.6-8.8)
Portal vein invasion	150 (67.0)	43 (70.5)	621 (48.0)	67 (64.4)
Hepatic vein invasion	43 (19.2)	9 (14.8)	155 (12.0)	11 (10.6)
Bile duct invasion	8 (3.6)	6 (9.8)	74 (5.7)	7 (6.7)
Lymph node metastasis	49 (21.9)	16 (26.2)	192 (14.8)	17 (16.3)
Distant metastasis	99 (44.2)	24 (39.3)	274 (21.2)	26 (25.0)
Modified UICC stage	n=224	n=61	n=1,284	n=103
Stage I	1 (0.4)	1 (1.6)	56 (4.4)	3 (2.9)
Stage II	11 (4.9)	4 (6.6)	243 (18.9)	11 (10.7)
Stage III	41 (18.3)	14 (23.0)	418 (32.6)	34 (33.0)
Stage IV-A	72 (32.1)	18 (29.5)	293 (22.8)	29 (28.2)
Stage IV-B	99 (44.2)	24 (39.3)	274 (21.3)	26 (25.2)
BCLC stage	n=212	n=58	n=1,167	n=98
0	0	0	15 (1.3)	1 (1.0)
A	8 (3.8)	3 (5.2)	184 (15.8)	10 (10.2)
B	10 (4.7)	1 (1.7)	116 (9.9)	4 (4.1)
C	180 (84.9)	50 (86.2)	603 (51.7)	82 (83.7)
D	14 (6.6)	4 (6.9)	249 (21.3)	1 (1.0)

Values are expressed as median (interquartile range) or number (%).

HBV, hepatitis B virus; HCV, hepatitis C virus; INR, international normalized ratio; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PIVKA-II, protein induced by vitamin K absence-II; MELD, Model for End Stage Liver Disease; UICC, Union for International Cancer Control; BCLC, Barcelona Clinic Liver Cancer.

*Miscellaneous therapies are defined as unclassifiable treatment modalities (i.e., combination therapies other than transarterial therapy and local ablation therapy); †Patients co-infected with HBV and HCV were also included; ‡Performance status was defined as follows: 0, fully active without symptoms; 1, ambulatory with symptoms; 2, bedridden <50% of the time; 3, bedridden >50% of the time but capable of self-care; 4, bedridden 100% of the time and incapable of self-care.